A treatment to starve brain tumours of blood has shown positive results in clinical trials, BBC News Online reports.
However, U.S. doctors say it is not yet clear whether the drug, AZD2171, will extend the lives of patients with some of the deadliest cancers.
The trials, published in Cancer Cell, were carried out on 16 patients at Massachusetts General Hospital with glioblastoma brain tumours.
In eight of them, the cancer shrank by half or more after treatment. The drug works by interfering with the tumour’s efforts to supply itself with enough blood as it grows by creating new blood vessels around it. Without enough blood, and the oxygen it carries, parts of the tumour cannot grow any bigger, and may start to die.